



Bayer-THU Collaboration

Call for Application

2024 Bayer Microfunding

Collaborate to Cure Hub China
Bayer Pharmaceuticals

拜耳处方药中国合作创新中心

Dec 2024



RESTRICTED



Introduction

Collaborate
TO CURE

About Bayer Microfunding

To encourage research translation in drug discovery, Bayer will support Tsinghua in three **Microfunding** projects by an aggregate amount of up to 1.2 million CNY per year.

- // Each Microfunding project can be funded with up to a total of 400 kCNY for a maximum duration of two years
- // Microfunding projects will be research projects in Bayer's interested area. The projects will be solely conducted by Tsinghua investigators without involvement of Bayer.
- // The funding is to support Tsinghua Investigators to freely explore innovation translation, therefore, any project results deriving from a Microfunding project will solely be owned by Tsinghua

Who May Apply?

- // Eligible applicants need to be full-time employees of Tsinghua at the time of applying and receiving the fund
- // Working in the School of Life Sciences, Tsinghua Medicine, School of Pharmaceutical Sciences or Department of Chemistry, School of Information Science and Technology of Tsinghua
- // Independent of having a project with Bayer or not
- // **Must not** be healthcare professionals, or employed by a hospital due to international compliance requirements
- // Members of the Joint Steering Committee (JSC) may not apply for the fund
- // Having a clear path of translating their research



Evaluation Process

Collaborate
TO CURE

// The proposal will be evaluated based on the following considerations:

1. Feasibility of translating your research to drug discovery
2. Innovation and breakthrough potential in solving current unmet needs in diseases and drug discovery
3. Research relevance to Bayer's areas of interest, including:

// Therapeutic areas in **Precision Oncology** (e.g. Precision molecular oncology, Targeted Radiotherapies, Next-gen Immuno-Oncology, ADCs), **Precision cardiorenal diseases** (e.g. Heart Failure, Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Chronic Kidney Disease, Autosomal Dominant Kidney Disease, Lupus Nephritis), **Neurology & Rare diseases** enabled by cell and gene therapy, and **Immunology & Inflammation** (e.g. SLE, IBD).

// Novel technologies/platforms that enable target identification/entry into druggability, specifically: Interactome analysis, methods for identification of new allosteric pockets and binders, multi-omics techniques, structural biology and biophysical methods (e.g. X-Ray, cryo-EM, AS MS, NMR, etc.), bioinformatics; Acceleration of learning cycles: Organ on drug to accelerate insights generation for new targets and cps, Prediction/ data science aspects specifically for acceleration of learning cycles

// Therapeutic modalities, Peptide binders, protein degraders, molecular glue, modalities derived from conjugation platforms (antibody, peptide, glyco, radio labelling), SMOL RNA binders, Antisense and siRNA therapeutics; Targeted drug delivery: e.g. organ specific LNPs, etc.

// The proposal provided will be evaluated by Bayer scientific experts and the Joint Steering Committee (JSC) from both Bayer and Tsinghua University



Obligation

// Use of Microfunding:

- // The Microfunding shall be used exclusively for the performance of the Microfunding projects
- // Microfunding cannot be used to fund equipment and infrastructure.

// Recipients of Bayer Microfunding Shall:

- // Provide a mid-term and final report to Bayer for the project progress
- // Acknowledge funding by Bayer in their talks and publications in related areas of interest



Application Process

1 Submit your proposal by **Jan 27th, 2025**:

// Please use the Application Form to submit an abstract of your research proposal or technology

// Please indicate in the abstract

// What unmet need your research addresses?

// What is the advantage/differentiation of your solution?

// IP situation

// Path forward for the translation of your research

2 Please note that only **non-confidential information should be provided**

3 Submit your proposal to Bayer and Tsinghua Alliance Managers

Duan Wang(王端)

Yuxin Li(李玉鑫)

Collaborate to Cure Hub China
Bayer Pharmaceuticals

Biomedical Innovation Office, Tsinghua
University

Mobile: +86 18221448381
E-mail: duan.wang@bayer.com

Tel: +86 10 62781816
Mobile: +86 13848615270
E-mail: yuxin-li@mail.tsinghua.edu.cn

4 Decision letters will be sent out in February 2025

Health for all, Hunger for none



Thank
you!